How I manage sickle cell patients with high transcranial doppler results

John Brewin, Banu Kaya, Subarna Chakravorty*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)


    Stroke is one of the most severe complications to affect children with sickle cell anaemia (SCA). Transcranial doppler (TCD) is an accurate and non-invasive method to determine stroke risk. Randomised controlled trials have demonstrated the efficacy of chronic transfusion therapy in stroke prevention based on risk stratification determined by TCD velocities. This has led to the regular use of TCD monitoring for children with SCA in order to determine stroke risk. Significant resource allocation is necessary to facilitate training, quality assurance and failsafe arrangements for non-attenders. In a subgroup of patients, chronic transfusions for primary stroke prevention can be replaced by hydroxycarbamide therapy, provided careful monitoring is undertaken; including repeat TCD studies at frequent intervals. The authors propose an evidence-based algorithm for the management of abnormal TCD velocities and discuss the role of this test in other clinical contexts, such as in Haemoglobin SC disease.

    Original languageEnglish
    JournalBritish Journal of Haematology
    Publication statusE-pub ahead of print - 2 Aug 2017


    • Sickle cell disease
    • Stroke
    • Transcranial doppler
    • Vasculopathy


    Dive into the research topics of 'How I manage sickle cell patients with high transcranial doppler results'. Together they form a unique fingerprint.

    Cite this